Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Shares Issued (2017 - 2025)

Historic Shares Issued for Vistagen Therapeutics (VTGN) over the last 13 years, with Q4 2025 value amounting to $2.3 million.

  • Vistagen Therapeutics' Shares Issued rose 13845.36% to $2.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $29.6 million, marking a year-over-year decrease of 4923.46%. This contributed to the annual value of $93.5 million for FY2024, which is N/A changed from last year.
  • Latest data reveals that Vistagen Therapeutics reported Shares Issued of $2.3 million as of Q4 2025, which was up 13845.36% from $27.9 million recorded in Q3 2025.
  • In the past 5 years, Vistagen Therapeutics' Shares Issued registered a high of $57.2 million during Q1 2024, and its lowest value of -$1.1 million during Q1 2025.
  • Moreover, its 5-year median value for Shares Issued was $970000.0 (2024), whereas its average is $5.9 million.
  • As far as peak fluctuations go, Vistagen Therapeutics' Shares Issued plummeted by 10535.28% in 2022, and later soared by 203919.87% in 2023.
  • Over the past 5 years, Vistagen Therapeutics' Shares Issued (Quarter) stood at $2.0 million in 2021, then plummeted by 95.41% to $89600.0 in 2022, then skyrocketed by 134.38% to $210000.0 in 2023, then soared by 361.9% to $970000.0 in 2024, then soared by 138.45% to $2.3 million in 2025.
  • Its last three reported values are $2.3 million in Q4 2025, $27.9 million for Q3 2025, and $397000.0 during Q2 2025.